Cochrane · systematic review · CD008521
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Bergman, H, Henschke, N, Hungerford, D, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
56
current version
GRADE rated
50
No studies
6
Included studies
NR
No studies 6 · 10.7%Ungraded 0 · 0%Very low 5 · 8.9%Low 10 · 17.9%Moderate 13 · 23.2%High 22 · 39.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRotarix compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.07 [0.03, 0.18] | 4 studies · 14976 participants | High |
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.1 [0.07, 0.14] | 6 studies · 18145 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.48 [0.37, 0.61] | 1 study · 3874 participants | Moderate Downgraded: risk of bias, imprecision |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.49 [0.4, 0.6] | 2 studies · 6269 participants | Moderate Downgraded: risk of bias, imprecision |
All‐cause death Rotarix vs placebo | RR 0.71 [0.17, 2.88] | 10 studies · 20361 participants | Low Downgraded: imprecision |
All serious adverse events Rotarix vs placebo | RR 0.89 [0.72, 1.1] | 12 studies · 18971 participants | High |
Serious adverse events: intussusception Rotarix vs placebo | RR 1.42 [0.52, 3.87] | 10 studies · 20773 participants | Low Downgraded: imprecision |
Rotarix compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.21 [0.16, 0.29] | 4 studies · 31671 participants | High |
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.23 [0.17, 0.29] | 3 studies · 23834 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.64 [0.52, 0.79] | 2 studies · 26479 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.74 [0.5, 1.09] | 2 studies · 23317 participants | Low Downgraded: imprecision, inconsistency |
All‐cause death Rotarix vs placebo | RR 1.27 [0.89, 1.81] | 9 studies · 77043 participants | Moderate Downgraded: imprecision |
All serious adverse events Rotarix vs placebo | RR 0.85 [0.76, 0.95] | 9 studies · 77069 participants | High |
Serious adverse events: intussusception Rotarix vs placebo | RR 0.72 [0.39, 1.32] | 6 studies · 75540 participants | Low Downgraded: imprecision |
Rotarix compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.42 [0.28, 0.61] | 4 studies · 15822 participants | High |
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.65 [0.51, 0.83] | 2 studies · 13768 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.73 [0.56, 0.95] | 2 studies · 5639 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.83 [0.72, 0.96] | 1 study · 2764 participants | High |
All‐cause death Rotarix vs placebo | RR 0.88 [0.63, 1.21] | 11 studies · 8374 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
All serious adverse events Rotarix vs placebo | RR 0.9 [0.77, 1.05] | 10 studies · 7674 participants | High |
Serious adverse events: intussusception Rotarix vs placebo | RR 1.49 [0.06, 36.63] | 5 studies · 17068 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
RotaTeq compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.03 [0.01, 0.11] | 5 studies · 7688 participants | High |
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.04 [0.01, 0.11] | 2 studies · 5442 participants | High |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
All‐cause death RotaTeq vs placebo | RR 1.24 [0.69, 2.22] | 6 studies · 72654 participants | Low Downgraded: imprecision |
All serious adverse events RotaTeq vs placebo | RR 0.92 [0.84, 1.01] | 5 studies · 70690 participants | High |
Serious adverse events: intussusception RotaTeq vs placebo | RR 0.69 [0.35, 1.38] | 9 studies · 73925 participants | Low Downgraded: imprecision |
RotaTeq compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.21 [0.11, 0.41] | 1 study · 3863 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
All‐cause death RotaTeq vs placebo | RR 0.33 [0.01, 8.18] | 2 studies · 4088 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
All serious adverse events RotaTeq vs placebo | RR 0.66 [0.14, 3.17] | 2 studies · 4082 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events: intussusception RotaTeq vs placebo | RR 5.01 [0.24, 104.29] | 2 studies · 4082 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
RotaTeq compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.43 [0.29, 0.64] | 2 studies · 6775 participants | High |
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.56 [0.41, 0.77] | 2 studies · 6744 participants | High |
Severe cases of all‐cause diarrhoea RotaTeq vs placebo | RR 0.8 [0.58, 1.11] | 1 study · 4085 participants | Moderate Downgraded: imprecision |
Severe cases of all‐cause diarrhoea RotaTeq vs placebo | RR 0.85 [0.74, 0.99] | 2 studies · 5977 participants | High |
All‐cause death RotaTeq vs placebo | RR 0.91 [0.68, 1.23] | 3 studies · 7706 participants | Moderate Downgraded: imprecision |
All serious adverse events RotaTeq vs placebo | RR 0.99 [0.72, 1.36] | 4 studies · 7730 participants | Moderate Downgraded: imprecision |
Serious adverse events: intussusception RotaTeq vs placebo | RR 0.33 [0.01, 8.16] | 2 studies · 7488 participants | Low Downgraded: imprecision |
Rotasiil compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotasiil vs placebo | RR 0.52 [0.33, 0.81] | 2 studies · 11008 participants | High |
Severe cases of rotavirus diarrhoea Rotasiil vs placebo | RR 0.56 [0.42, 0.74] | 2 studies · 11008 participants | High |
Severe cases of all‐cause diarrhoea Rotasiil vs placebo | RR 0.92 [0.84, 1.01] | 2 studies · 11008 participants | High |
Severe cases of all‐cause diarrhoea Rotasiil vs placebo | RR 0.94 [0.88, 1.01] | 2 studies · 11008 participants | High |
All‐cause death Rotasiil vs placebo | RR 1.14 [0.82, 1.59] | 2 studies · 11586 participants | Moderate Downgraded: imprecision |
All serious adverse events Rotasiil vs placebo | RR 0.98 [0.92, 1.04] | 3 studies · 11646 participants | High |
Serious adverse events: intussusception Rotasiil vs placebo | RR 0.98 [0.35, 2.74] | 2 studies · 11586 participants | Low Downgraded: imprecision |
Rotavac compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.43 [0.3, 0.6] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.46 [0.35, 0.6] | 1 study · 6541 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea Rotavac vs placebo | RR 0.84 [0.71, 0.98] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea Rotavac vs placebo | no estimate extracted | NR | No studies |
All‐cause death Rotavac vs placebo | RR 0.88 [0.5, 1.56] | 2 studies · 8155 participants | Very low Downgraded: imprecision, indirectness |
All serious adverse events Rotavac vs placebo | RR 0.93 [0.85, 1.02] | 3 studies · 8210 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events: intussusception Rotavac vs placebo | RR 1.33 [0.35, 5.02] | 4 studies · 8582 participants | Very low Downgraded: imprecision, indirectness |
RV1 compared to placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.16 [0.09, 0.26] | 7 studies · 43779 participants | High |
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.18 [0.14, 0.23] | 9 studies · 36002 participants | High |
Severe cases of all‐cause diarrhoea RV1 vs placebo | RR 0.59 [0.47, 0.74] | 3 studies · 28051 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Severe episodes of all‐cause diarrhoea RV1 vs placebo | Rate Ratio 0.63 [0.56, 0.71] | 2 studies · 39091 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
All‐cause death RV1 vs placebo | RR 1.22 [0.87, 1.71] | 22 studies · 97597 participants | Low Downgraded: risk of bias, imprecision |
All serious adverse events RV1 vs placebo | RR 0.88 [0.83, 0.93] | 24 studies · 96233 participants | High |
Serious adverse events: intussusception RV1 vs placebo | RR 0.69 [0.45, 1.04] | 17 studies · 96513 participants | Low Downgraded: risk of bias, imprecision |
RV1 compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.37 [0.23, 0.6] | 3 studies · 6114 participants | High |
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.65 [0.51, 0.83] | 2 studies · 13768 participants | High |
Severe cases of all‐cause diarrhoea RV1 vs placebo | RR 0.73 [0.56, 0.95] | 2 studies · 5639 participants | High |
Severe cases of all‐cause diarrhoea RV1 vs placebo | RR 0.82 [0.71, 0.95] | 1 study · 2764 participants | Moderate Downgraded: imprecision, indirectness |
All‐cause death RV1 vs placebo | RR 0.88 [0.64, 1.22] | 8 studies · 8181 participants | Low Downgraded: imprecision |
All serious adverse events RV1 vs placebo | RR 0.89 [0.76, 1.04] | 7 studies · 7481 participants | High |
Serious adverse events: intussusception RV1 vs placebo | RR 1.49 [0.06, 36.63] | 4 studies · 17492 participants | Low Downgraded: imprecision |
RV5 compared to placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.08 [0.03, 0.22] | 5 studies · 4132 participants | Moderate Downgraded: imprecision |
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.18 [0.08, 0.39] | 4 studies · 7318 participants | Moderate Downgraded: imprecision, inconsistency |
Severe all‐cause diarrhoea RV5 vs placebo | no estimate extracted | NR | No studies |
Severe all‐cause diarrhoea RV5 vs placebo | no estimate extracted | NR | No studies |
All‐cause death RV5 vs placebo | RR 1.13 [0.65, 1.96] | 9 studies · 77642 participants | Low Downgraded: imprecision |
All serious adverse events RV5 vs placebo | RR 0.93 [0.86, 1.02] | 8 studies · 75672 participants | High |
Serious adverse events: intussusception RV5 vs placebo | RR 0.77 [0.41, 1.45] | 12 studies · 78907 participants | Low Downgraded: imprecision |
RV5 compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.43 [0.29, 0.62] | 2 studies · 5916 participants | High |
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.59 [0.43, 0.82] | 2 studies · 5885 participants | High |
Severe cases of all‐cause diarrhoea RV5 vs placebo | RR 0.8 [0.58, 1.11] | 1 study · 4085 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea RV5 vs placebo | RR 0.85 [0.75, 0.98] | 2 studies · 5977 participants | High |
All‐cause death RV5 vs placebo | RR 0.92 [0.68, 1.24] | 3 studies · 6806 participants | Low Downgraded: imprecision |
All serious adverse events RV5 vs placebo | RR 0.92 [0.66, 1.28] | 4 studies · 6830 participants | Moderate Downgraded: imprecision |
Serious adverse events: intussusception RV5 vs placebo | no estimate extracted | 2 studies · 6588 participants | Low Downgraded: imprecision |
Rotavac compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.43 [0.3, 0.6] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.46 [0.35, 0.6] | 1 study · 6541 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea Rotavac vs placebo | RR 0.84 [0.71, 0.98] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
All‐cause death Rotavac vs placebo | RR 0.92 [0.52, 1.62] | 2 studies · 8155 participants | Very low Downgraded: imprecision, indirectness |
All serious adverse events Rotavac vs placebo | RR 0.93 [0.85, 1.02] | 3 studies · 8210 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events: intussusception Rotavac vs placebo | RR 1.33 [0.35, 5.02] | 4 studies · 8582 participants | Very low Downgraded: imprecision, indirectness |
RV1 compared to placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.16 [0.09, 0.26] | 7 studies · 43779 participants | High |
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.18 [0.14, 0.23] | 9 studies · 36002 participants | High |
Severe cases of all‐cause diarrhoea RV1 vs placebo | RR 0.59 [0.47, 0.74] | 3 studies · 28051 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Severe episodes of all‐cause diarrhoea RV1 vs placebo | Rate Ratio 0.63 [0.56, 0.71] | 2 studies · 39091 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
All‐cause death RV1 vs placebo | RR 1.22 [0.87, 1.71] | 22 studies · 97597 participants | Low Downgraded: risk of bias, imprecision |
All serious adverse events RV1 vs placebo | RR 0.88 [0.83, 0.93] | 24 studies · 96233 participants | High |
Serious adverse events: intussusception RV1 vs placebo | RR 0.69 [0.45, 1.04] | 17 studies · 96513 participants | Low Downgraded: risk of bias, imprecision |
RV1 compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.37 [0.23, 0.6] | 3 studies · 6114 participants | High |
Severe cases of rotavirus diarrhoea RV1 vs placebo | RR 0.65 [0.51, 0.83] | 2 studies · 13768 participants | High |
Severe cases of all‐cause diarrhoea RV1 vs placebo | RR 0.73 [0.56, 0.95] | 2 studies · 5639 participants | High |
Severe cases of all‐cause diarrhoea RV1 vs placebo | RR 0.82 [0.71, 0.95] | 1 study · 2764 participants | Moderate Downgraded: imprecision, indirectness |
All‐cause death RV1 vs placebo | RR 0.88 [0.64, 1.22] | 8 studies · 8181 participants | Low Downgraded: imprecision |
All serious adverse events RV1 vs placebo | RR 0.89 [0.76, 1.04] | 7 studies · 7481 participants | High |
Serious adverse events: intussusception RV1 vs placebo | RR 1.49 [0.06, 36.63] | 4 studies · 17492 participants | Low Downgraded: imprecision |
RV5 compared to placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.08 [0.03, 0.22] | 5 studies · 4132 participants | Moderate Downgraded: imprecision |
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.18 [0.08, 0.39] | 4 studies · 7318 participants | Moderate Downgraded: imprecision, inconsistency |
Severe all‐cause diarrhoea RV5 vs placebo | no estimate extracted | NR | No studies |
Severe all‐cause diarrhoea RV5 vs placebo | no estimate extracted | NR | No studies |
All‐cause death RV5 vs placebo | RR 1.13 [0.65, 1.96] | 9 studies · 77642 participants | Low Downgraded: imprecision |
All serious adverse events RV5 vs placebo | RR 0.93 [0.86, 1.02] | 8 studies · 75672 participants | High |
Serious adverse events: intussusception RV5 vs placebo | RR 0.77 [0.41, 1.45] | 12 studies · 78907 participants | Low Downgraded: imprecision |
RV5 compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.43 [0.29, 0.62] | 2 studies · 5916 participants | High |
Severe cases of rotavirus diarrhoea RV5 vs placebo | RR 0.59 [0.43, 0.82] | 2 studies · 5885 participants | High |
Severe cases of all‐cause diarrhoea RV5 vs placebo | RR 0.8 [0.58, 1.11] | 1 study · 4085 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea RV5 vs placebo | RR 0.85 [0.75, 0.98] | 2 studies · 5977 participants | High |
All‐cause death RV5 vs placebo | RR 0.92 [0.68, 1.24] | 3 studies · 6806 participants | Low Downgraded: imprecision |
All serious adverse events RV5 vs placebo | RR 0.92 [0.66, 1.28] | 4 studies · 6830 participants | Moderate Downgraded: imprecision |
Serious adverse events: intussusception RV5 vs placebo | no estimate extracted | 2 studies · 6588 participants | Low Downgraded: imprecision |
Rotavac compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.43 [0.3, 0.6] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.46 [0.35, 0.6] | 1 study · 6541 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea Rotavac vs placebo | RR 0.84 [0.71, 0.98] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
All‐cause death Rotavac vs placebo | RR 0.92 [0.52, 1.62] | 2 studies · 8155 participants | Very low Downgraded: imprecision, indirectness |
All serious adverse events Rotavac vs placebo | RR 0.93 [0.85, 1.02] | 3 studies · 8210 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events: intussusception Rotavac vs placebo | RR 1.33 [0.35, 5.02] | 4 studies · 8582 participants | Very low Downgraded: imprecision, indirectness |
RV1 compared to placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe rotavirus diarrhoea RV1 vs placebo | RR 0.14 [0.07, 0.26] | 6 studies · 40631 participants | High |
Severe rotavirus diarrhoea RV1 vs placebo | RR 0.15 [0.12, 0.2] | 8 studies · 32854 participants | High |
Severe episodes of all‐cause diarrhoea RV1 vs placebo | Rate Ratio 0.6 [0.5, 0.72] | 1 study · 17867 participants | Moderate Downgraded: risk of bias |
Severe episodes of all‐cause diarrhoea RV1 vs placebo | Rate Ratio 0.63 [0.56, 0.71] | 2 studies · 39091 participants | Moderate Downgraded: risk of bias |
All‐cause death RV1 vs placebo | RR 1.27 [0.89, 1.81] | 18 studies · 93321 participants | Low Downgraded: imprecision |
All serious adverse events RV1 vs placebo | RR 0.9 [0.84, 0.95] | 20 studies · 91957 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events: intussusception RV1 vs placebo | RR 0.87 [0.52, 1.46] | 11 studies · 91832 participants | Low Downgraded: imprecision |
RV1 compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe rotavirus diarrhoea RV1 vs placebo | RR 0.37 [0.18, 0.75] | 2 studies · 5414 participants | Moderate Downgraded: indirectness |
Severe rotavirus diarrhoea RV1 vs placebo | RR 0.58 [0.42, 0.79] | 1 study · 2764 participants | Moderate Downgraded: indirectness |
Severe all‐cause diarrhoea RV1 vs placebo | RR 0.66 [0.44, 0.98] | 1 study · 4939 participants | Moderate Downgraded: indirectness |
Severe all‐cause diarrhoea RV1 vs placebo | RR 0.82 [0.71, 0.95] | 1 study · 2764 participants | Moderate Downgraded: indirectness |
All‐cause death RV1 vs placebo | RR 0.88 [0.64, 1.22] | 7 studies · 7481 participants | Low Downgraded: imprecision |
All serious adverse events RV1 vs placebo | RR 0.89 [0.76, 1.04] | 7 studies · 7481 participants | Moderate Downgraded: risk of bias |
Serious adverse events: intussusception RV1 vs placebo | RR 1.49 [0.06, 36.63] | 2 studies · 5414 participants | Very low Downgraded: imprecision, indirectness |
RV5 compared to placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe rotavirus diarrhoea RV5 vs placebo | RR 0.13 [0.04, 0.45] | 3 studies · 2344 participants | Moderate Downgraded: imprecision |
Severe rotavirus diarrhoea RV5 vs placebo | RR 0.18 [0.07, 0.5] | 3 studies · 3190 participants | Moderate Downgraded: imprecision |
Severe all‐cause diarrhoea RV5 vs placebo | RR 0.28 [0.16, 0.48] | 1 study · 1029 participants | Low Downgraded: risk of bias, imprecision |
Severe all‐cause diarrhoea RV5 vs placebo | RR 0.04 [0, 0.7] | 1 study · 1029 participants | Low Downgraded: risk of bias, imprecision |
All‐cause death RV5 vs placebo | RR 1.18 [0.67, 2.08] | 8 studies · 73603 participants | Low Downgraded: imprecision |
All serious adverse events RV5 vs placebo | RR 0.92 [0.84, 1.01] | 7 studies · 71638 participants | High |
Serious adverse events: intussusception RV5 vs placebo | RR 0.67 [0.34, 1.31] | 11 studies · 74874 participants | Low Downgraded: imprecision |
RV5 compared to placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe rotavirus diarrhoea RV5 vs placebo | RR 0.43 [0.29, 0.62] | 2 studies · 5916 participants | High |
Severe rotavirus diarrhoea RV5 vs placebo | RR 0.59 [0.43, 0.82] | 2 studies · 5885 participants | High |
Severe all‐cause diarrhoea RV5 vs placebo | RR 0.8 [0.58, 1.11] | 1 study · 4085 participants | Moderate Downgraded: indirectness |
Severe all‐cause diarrhoea RV5 vs placebo | RR 0.85 [0.75, 0.98] | 2 studies · 5977 participants | High |
All‐cause death RV5 vs placebo | RR 0.93 [0.69, 1.25] | 2 studies · 6604 participants | Low Downgraded: imprecision |
All serious adverse events RV5 vs placebo | RR 0.93 [0.66, 1.33] | 2 studies · 6588 participants | Moderate Downgraded: imprecision |
Serious adverse events: intussusception RV5 vs placebo | no estimate extracted | 2 studies · 6588 participants | Low Downgraded: imprecision |
RV1 compared to placebo for preventing rotavirus diarrhoea ‐ first year follow‐up and safety outcomes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rotavirus diarrhoea: of any severity RV1 vs placebo | RR 0.3 [0.18, 0.5] | 7 studies · 12130 participants | Moderate Downgraded: risk of bias, inconsistency |
Rotavirus diarrhoea: severe RV1 vs placebo | RR 0.2 [0.11, 0.35] | 7 studies · 35004 participants | Moderate Downgraded: risk of bias, inconsistency |
Rotavirus diarrhoea: requiring hospitalization RV1 vs placebo | RR 0.21 [0.11, 0.41] | 5 studies · 28219 participants | High |
All‐cause diarrhoea: severe cases RV1 vs placebo | RR 0.58 [0.4, 0.84] | 2 studies · 8291 participants | Low Downgraded: inconsistency |
All‐cause death RV1 vs placebo | OR 0.99 [0.77, 1.26] | 24 studies · 100517 participants | High |
Serious adverse events RV1 vs placebo | RR 0.89 [0.84, 0.94] | 28 studies · 95178 participants | Moderate Downgraded: risk of bias |
Intussusception RV1 vs placebo | OR 0.93 [0.53, 1.61] | 11 studies · 98456 participants | High |
RV1 compared to placebo for preventing rotavirus diarrhoea ‐ second year follow‐up
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rotavirus diarrhoea: of any severity RV1 vs placebo | RR 0.3 [0.21, 0.43] | 6 studies · 8041 participants | Moderate Downgraded: risk of bias, inconsistency |
Rotavirus diarrhoea: severe RV1 vs placebo | RR 0.16 [0.12, 0.21] | 8 studies · 32854 participants | High |
Rotavirus diarrhoea: requiring hospitalization RV1 vs placebo | RR 0.17 [0.11, 0.25] | 5 studies · 21664 participants | High |
All‐cause diarrhoea: severe cases RV1 vs placebo | RR 0.49 [0.4, 0.6] | 2 studies · 6269 participants | Moderate |
RV5 compared to placebo for preventing rotavirus diarrhoea ‐ first year follow‐up and safety outcomes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rotavirus diarrhoea: of any severity RV5 vs placebo | RR 0.27 [0.22, 0.33] | 4 studies · 7614 participants | High |
Rotavirus diarrhoea: severe RV5 vs placebo | RR 0.23 [0.08, 0.71] | 3 studies · 6953 participants | High |
Rotavirus diarrhoea: requiring hospitalization RV5 vs placebo | RR 0.04 [0.02, 0.1] | 1 study · 57134 participants | Moderate Downgraded: risk of bias |
All‐cause diarrhoea: severe cases RV5 vs placebo | RR 0.28 [0.16, 0.48] | 1 study · 1029 participants | Low Downgraded: risk of bias, imprecision |
All‐cause death RV5 vs placebo | OR 0.98 [0.75, 1.29] | 6 studies · 78582 participants | Moderate Downgraded: risk of bias |
Serious adverse events RV5 vs placebo | RR 0.93 [0.85, 1.01] | 7 studies · 77480 participants | Moderate Downgraded: risk of bias |
Intussusception RV5 vs placebo | OR 0.8 [0.37, 1.71] | 6 studies · 76090 participants | Moderate Downgraded: risk of bias |
RV5 compared to placebo for preventing rotavirus diarrhoea ‐ second year follow‐up
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rotavirus diarrhoea: of any severity RV5 vs placebo | RR 0.51 [0.36, 0.72] | 4 studies · 9784 participants | Low Downgraded: risk of bias, inconsistency |
Rotavirus diarrhoea: severe RV5 vs placebo | RR 0.44 [0.22, 0.88] | 4 studies · 9783 participants | Low Downgraded: risk of bias, inconsistency |
All‐cause diarrhoea: severe cases RV5 vs placebo | RR 0.8 [0.57, 1.13] | 3 studies · 8533 participants | Moderate Downgraded: inconsistency |